{"schema_version":"1","generated_at":"2026-11-01T08:52:48.136Z","data_as_of":null,"url":"https://www.findmykol.com/kol/sankalp-arora","json_url":"https://www.findmykol.com/kol/sankalp-arora/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"sankalp-arora","name":"Sankalp Arora","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Birmingham","state":"AL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1700494200","orcid":"0000-0002-8162-4119","openalex":"A5020226783"},"summary":"Sankalp Arora is an Oncology physician. OpenAlex indexes 67 publications with 283 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":67,"cited_by_count":283,"h_index":10,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":9,"program_years":{"first":2021,"last":null},"rows_total":10,"shown":3,"withheld":7,"rows":[{"payer":"Syndax Pharmaceuticals, Inc.","program_year":2025,"amount_usd":153.7,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1700494200"},{"payer":"Astellas Pharma US Inc","program_year":2025,"amount_usd":151,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1700494200"},{"payer":"GENZYME CORPORATION","program_year":2025,"amount_usd":139.79,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1700494200"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1700494200","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-25-0229","status":"verified"},{"title":"Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024015285","status":"verified"},{"title":"Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline <scp>FLT3</scp> Inhibitor‐Based Therapy in <scp> <i>FLT3</i> </scp> ‐Mutated <scp>AML</scp>","year":2025,"journal":"American Journal of Hematology","source_url":"https://doi.org/10.1002/ajh.70053","status":"verified"},{"title":"A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-5226","status":"verified"},{"title":"Outcomes of patients with newly diagnosed acute myeloid leukemia with <i>FLT3</i>‐tyrosine kinase domain mutations: Prognostic implications of <i>NPM1</i> co‐mutation","year":2025,"journal":"Cancer","source_url":"https://doi.org/10.1002/cncr.70032","status":"verified"}],"source":"works"},"contact":{"address_1":"625 19TH ST S","city":"Birmingham","state":"AL","zip":"352331900","phone":"205-934-2490","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1700494200","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":7,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2026-05-05","provider_certified":"2026-05-05","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}